BioNTech stock falls as earnings beat expectations, but show falling demand for COVID-19 vaccines

The U.S.-listed shares of BioNTech SE BNTX fell 2.7% in premarket expectations, as profit and revenue beat expectations but fell from a year ago due to lower demand for COVID-19 vaccines, and indicated demand would fall further. Net income fell to EUR2.28 billion , or EUR9.26 a share, from EUR#.17 billion, or EUR12.18 a share, in the year-ago period. The FactSet consensus for earnings per share was EUR7.78. Revenue fell 22.7% to EUR4.28 billion , above the FactSet consensus of EUR3.65 billion.

7% in premarket expectations, as profit and revenue beat expectations but fell from a year ago due to lower demand for COVID-19 vaccines, and indicated demand would fall further. Net income fell to EUR2.28 billion , or EUR9.26 a share, from EUR#.17 billion, or EUR12.18 a share, in the year-ago period. The FactSet consensus for earnings per share was EUR7.78. Revenue fell 22.7% to EUR4.28 billion , above the FactSet consensus of EUR3.65 billion.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

MarketWatch /  🏆 3. in AU

I wonder why...

Australia Australia Latest News, Australia Australia Headlines